Major US Expert Group to Vote on Modifying Baby Hepatitis B Vaccine Recommendation
Following a postponement and a particularly heated session, a federal vaccine advisory panel was scheduled to decide on Friday concerning altering the long-held guideline that all newborns be vaccinated against hepatitis B.
Fiery Exchange and a Deferred Vote
The first day of the meeting on Thursday was marked by fiery discussion over limiting availability to the hepatitis B vaccine for newborns and a choice to delay the ballot by a day to provide committee members extra time to scrutinize the phrasing. The committee, which advises the Centers for Disease Control and Prevention on vaccination protocols, had previously delayed on two occasions.
“Is there any definitive data of damage of giving this vaccination before 30 days? Or is this conjecture?” questioned one committee member.
In reply, another participant stated, “There is inadequate data about the enduring danger.”
Current Guidelines and Potential Impact
The vaccine is currently suggested for all infants within 24 hours of being born to prevent infection of hepatitis B, which can lead to significant hepatic injury. It has been given to more than a billion persons for in excess of thirty years.
The Georgia assembly provided no new evidence of harms caused by the vaccine. Specialists note any change to the existing hepatitis B immunization timeline could have major and extensive implications for infant and child health in the United States.
Group Membership and Recent Changes
The expert committee can only provide advice to the head of the CDC. The committee's composition has undergone changes this week, with the declaration that the committee’s most recent chair would depart for an agency job and be succeeded by a cardiac doctor who has been critical of other vaccines.
The board includes multiple vaccination critics who are in agreement with a aim to revamp – and potentially, in some cases, scrap – long-established vaccine advisories.
